Involvement of μ-opioid receptor in methamphetamine-induced behavioral sensitization

Current Neuropharmacology

Volumn 9, Issue 1, 2011, Pages 215-218

  Tien, Lu Tai ^a   Ho, Ing Kang ^b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

opioid receptor; Locomotor activity; Meth induced sensitization; Psychostimulants

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; AMPHETAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HOMOVANILLIC ACID; METHAMPHETAMINE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ARTICLE; BEHAVIOR CHANGE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MEGADOSE; DRUG SEEKING BEHAVIOR; DRUG WITHDRAWAL; HUMAN; LOCOMOTION; LOW DRUG DOSE; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; OUTCOME ASSESSMENT; RECEPTOR BINDING; SENSITIZATION; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 79953044432     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015911795016949     Document Type: Article

References (35)

1. Kerdsan, W., Thanoi, S., Nudmamud-Thanoi, S. Changes in glutamate/ NMDA receptor subunit 1 expression in rat brain after acute and subacute exposure to methamphetamine. J. Biomed. Biotechnol., 2009, 2009, 329631-329634.
2. Robinson, T.E., Berridge, K.C. Incentive-sensitization and addiction. Addiction, 2001, 96, 103-114.
3. Nishikawa, T., Mataga, N., Takashima, M., Toru, M. Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur. J. Pharmacol., 1983, 88, 195-203.
4. Yang, M.H., Kim, S., Jung, M.S., Shim, J.H., Ryu, N.K., Yook, Y.J., Jang, C.G., Bahk, Y.Y., Kim, K.W., Park, J.H. Proteomic analysis of methamphetamine-induced reinforcement processes within the mesolimbic dopamine system. Addict. Biol., 2008, 13, 287-294.
5. Ford, C.P., Mark, G.P., Williams, J.T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci., 2006, 26, 2788-2797.
6. Faure, A., Reynolds, S.M., Richard, J.M., Berridge, K.C. Mesolimbic dopamine in desire and dread: enabling motivation to be generated by localized glutamate disruptions in nucleus accumbens. J. Neurosci., 2008, 28, 7148-7192.
7. Cruz, H.G., Ivanova, T., Lunn, M.L., Stoffel, M., Slesinger, P.A., Luscher, C. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat. Neurosci., 2004, 7, 153- 159.
8. Devine, D.P., Leone, P., Pocock, D., Wise, R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther., 1993, 266, 1236-1246.
9. Di Chiara, G., Imperato, A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther., 1988, 244, 1067-1080.
10. Fadda, P., Scherma, M., Fresu, A., Collu, M., Fratta, W. Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. Synapse, 2005, 56, 29-38.
11. Spyraki, C., Fibiger, H.C., Phillips, A.G. Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system. Psychopharmacology, 1983, 79, 278-283.
12. Zito, K.A., Vickers, G., Roberts, D.C. Disruption of cocaine and heroin self-administration following kainic acid lesions of the nucleus accumbens. Pharmacol. Biochem. Behav., 1985, 23, 1029-1036.
13. Bozarth, M.A., Wise, R.A. Heroin reward is dependent on a dopaminergic substrate. Life Sci., 1981, 29, 1881-1886.
14. Chiu, C.T., Ma, T., Ho, I.K. Attenuation of methamphetamineinduced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res. Bull., 2005, 67, 100-109.
15. Chiu, C.T., Ma, T., Ho, I.K. Methamphetamine-induced behavioral sensitization in mice: alterations in mu-opioid receptor. J. Biomed. Sci., 2006, 13, 797-811.
16. Shen, X., Purser, C., Tien, L.T., Chiu, C.T., Paul, I.A., Baker, R., Loh, H.H., Ho, I.K., Ma, T. μ-opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization. J. Neurosci. Res., 2010, 88, 2294-2302.
17. Lan, K.C., Ma, T., Lin-Shiau, S.Y., Liu, S.H., Ho, I.K. Methamphetamine- elicited alterations of dopamine- and serotoninmetabolite levels within mu-opioid receptor knockout mice: a microdialysis study. J. Biomed. Sci., 2008, 15, 391-340.
18. Tien, L.T., Ho, I.K., Loh, H.H., Ma, T. Role of mu-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice. J. Neurosci. Res., 2007, 85, 673-680.
19. Robinson, T.E., Becker, J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res., 1986, 396, 157-198.
20. Itzhak, Y., Ali, S.F. Behavioral consequences of methamphetamine- induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction. Ann. N.Y. Acad. Sci., 2002, 965, 127-135.
21. Phillips, T.J., Dickinson, S., Burkhart-Kasch, S. Behavioral sensitization to drug stimulant effects in C57BL/6J and DBA/2J inbred mice. Behav. Neurosci., 1994, 108, 789-803.
22. Ujike, H., Onoue, T., Akiyama, K., Hamamura, T., Otsuki, S. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology, 1989, 98, 89-92.
23. Yang, M.H., Jung, M.S., Lee, M.J., Yoo, K.H., Yook, Y.J., Park, E.Y., Choi, S.H., Suh, Y.J., Kim, K.W., Park, J.H. Gene expression profiling of the rewarding effect caused by methamphetamine in the mesolimbic dopamine system. Mol. Cells, 2008, 26, 121-130.
24. Kubota, Y., Inagaki, S., Kito, S., Takagi, H., Smith, A.D. Ultrastructural evidence of dopaminergic input to enkephalinergic neurons in rat neostriatum. Brain Res., 1986, 367, 374-378.
25. Sesack, S.R., Pickel, V.M. Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions. J. Neurosci., 1992, 12, 1335-1350.
26. Horner, K.A., Keefe, K.A. Regulation of psychostimulant-induced preprodynorphin, c-fos and zif/268 messenger RNA expression in the rat dorsal striatum by mu opioid receptor blockade. Eur. J. Pharmacol., 2006, 532, 61-73.
27. Woo, S.K., Hitzemann, R.J., Loh, H.H. Specific opioidamphetamine interactions in the caudate putamen. Psychopharmacology, 1985, 85, 371-376.
28. Lan, K.C., Chang, A.C., Liu, S.H., Ho, I.K., Lin-Shiau, S.Y. Enhancing effects of morphine on methamphetamine-induced reinforcing behavior and its association with dopamine release and metabolism in mice. J. Neurochem., 2009, 109, 382-392.
29. Kuribara, H., Uchihashi, Y. Dopamine antagonists can inhibit methamphetamine sensitization, but not cocaine sensitization, when assessed by ambulatory activity in mice. J. Pharm. Pharmacol., 1993, 45, 1042-1045.
30. Stoof, J.C., Kebabian, J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature, 1981, 294, 366-368.
31. Vonk, A., Reinart, R., Rinken, A. Modulation of adenylyl cyclase activity in rat striatal homogenate by dopaminergic receptors. J. Pharmacol. Sci., 2008, 108, 63-70.
32. Greengard, P., Allen, P.B., Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron, 1999, 23, 435-447.
33. Nestler, E.J., Aghajanian, G.K. Molecular and cellular basis of addiction. Science, 1997, 278, 58-63.
34. Hiroi, N., Fienberg, A.A., Haile, C.N., Alburges, M., Hanson, G.R., Greengard, P., Nestler, E.J. Neuronal and behavioral abnormalities in striatal function in DARPP-32-mutant mice. Eur. J. Neurosci., 1999, 11, 1114-1118.
35. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A., O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D.C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.J., Hyman, S.E., Surmeier, D.J., Girault, J., Nestler, E.J., Greengard, P. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science, 1998, 281, 838-842.